Kazia Therapeuti - KZIA STOCK NEWS

Kazia Therapeutics announced results from the GBM-AGILE Phase II/III clinical trial evaluating paxalisib for glioblastoma. The trial showed a 3.8-month improvement in overall survival (OS) for newly diagnosed unmethylated patients, a 33% increase compared to the standard of care (SOC). The median OS for paxalisib-treated patients was 15.54 months versus 11.89 months for SOC. No new safety concerns were identified. Paxalisib did not show efficacy in recurrent disease populations. Based on these results, Kazia plans to discuss accelerated approval with the FDA. Full data will be presented later this year.

Kazia Therapeutics (NASDAQ: KZIA) has announced new data presentations from its lead program, paxalisib, at the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) in Philadelphia from June 29 to July 2, 2024. The data includes results from the Phase 2 PNOC DMG-ACT study evaluating paxalisib in combination with ONC201, revealing median overall survival rates of 13.2 months (Cohort 1), 15.8 months (Cohort 2), and 8.8 months (Cohort 3). Additional presentations will cover preclinical data on paxalisib combined with an HDAC inhibitor and gemcitabine for treating atypical teratoid/rhabdoid tumors. Concurrently, Kazia's research has been published in the European Journal of Cancer, emphasizing the need for mutation-specific, CNS-penetrant inhibitors for pediatric Diffuse Midline Glioma (DMG). These developments highlight potential advancements in treating pediatric brain cancers.

Kazia Therapeutics (NASDAQ: KZIA) has been granted an additional 180-day extension by Nasdaq, until November 18, 2024, to comply with the Minimum Bid Price Requirement of $1.00 per share. Initially notified of the deficiency on November 20, 2023, Kazia failed to regain compliance by the original deadline of May 20, 2024. Despite this, Nasdaq extended the compliance period based on the company's adherence to other listing criteria and its intent to resolve the issue. Kazia may employ solutions like a ratio change of its American Depositary Shares (ADSs). Failure to comply could lead to delisting, though appeals are possible. The extension does not affect current operations or trading under the ticker 'KZIA' on The Nasdaq Capital Market.

Kazia Therapeutics reported successful completion of stage 1 of the EVT801 Phase 1 clinical trial in advanced cancer patients. The Safety Review Team confirmed meeting primary and secondary objectives, determining a recommended phase 2 dose at 400mg BID. EVT801 showed promising clinical activity, especially in patients with advanced ovarian cancer. The trial included 26 patients across six dosing cohorts, with EVT801 being well-tolerated. CEO Dr. John Friend emphasized the need for new therapies in high-grade serous ovarian cancer patients.

Kazia Therapeutics (KZIA) announces an exclusive licensing agreement with Sovargen Co., to develop paxalisib for intractable epilepsy in FCD T2 and TSC diseases. The agreement includes upfront payment, milestone payments, and revenue sharing. Kazia CEO Dr. John Friend expresses excitement for the potential impact of paxalisib in CNS diseases.

Kazia Therapeutics (KZIA) presents new data on pipeline molecules at AACR, showing promising results for EVT801 and paxalisib in cancer treatment. The data includes phase 1 study results and combination therapy efficacy for atypical teratoid/rhabdoid tumors.

Kazia Therapeutics Limited announces positive results from a Phase I trial combining paxalisib with radiation therapy for treating patients with PI3K pathway mutation brain metastases. The study shows promising safety and clinical activity, with the primary endpoint achieved.

Kazia Therapeutics (KZIA) appoints pharma industry executive Robert Apple as Non-Executive Director and Bryce Carmine as Chairman. Mr. Apple brings over 25 years of leadership experience, including roles at Antares Pharma and InKine Pharmaceutical. Mr. Carmine has a distinguished career at Eli Lilly & Co. CEO Dr. John Friend expressed delight with the appointments, emphasizing the value of their expertise for the company's growth.

Kazia Therapeutics Limited (NASDAQ: KZIA) closed a purchase and sale of up to 4,444,445 of the Company's American Depositary Shares (ADSs) at a purchase price of $0.45 per ADS, raising approximately $2 million in gross proceeds. The Company also issued unregistered warrants to purchase up to 4,444,445 ADSs at an exercise price of $0.583 per ADS, with H.C. Wainwright & Co. acting as the exclusive placement agent.